"Ribavirin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.
Descriptor ID |
D012254
|
MeSH Number(s) |
D13.570.800.790
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ribavirin".
Below are MeSH descriptors whose meaning is more specific than "Ribavirin".
This graph shows the total number of publications written about "Ribavirin" by people in this website by year, and whether "Ribavirin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 1 | 1 | 2 |
2002 | 1 | 0 | 1 |
2003 | 0 | 9 | 9 |
2004 | 2 | 6 | 8 |
2005 | 2 | 2 | 4 |
2006 | 3 | 1 | 4 |
2007 | 1 | 1 | 2 |
2008 | 3 | 2 | 5 |
2009 | 3 | 1 | 4 |
2010 | 2 | 2 | 4 |
2012 | 4 | 0 | 4 |
2013 | 4 | 2 | 6 |
2014 | 5 | 3 | 8 |
2015 | 2 | 1 | 3 |
2016 | 2 | 4 | 6 |
2017 | 38 | 50 | 88 |
2018 | 27 | 42 | 69 |
2019 | 6 | 14 | 20 |
2020 | 5 | 16 | 21 |
2021 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Ribavirin" by people in Profiles.
-
Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study. PLoS One. 2021; 16(6):e0252984.
-
Transformation of antiviral ribavirin during ozone/PMS intensified disinfection amid COVID-19 pandemic. Sci Total Environ. 2021 Oct 10; 790:148030.
-
Acute and severe ribavirin-associated hyperuricemia and acute kidney injury: An underrecognized adverse effect. Am J Health Syst Pharm. 2021 04 22; 78(9):794-799.
-
Broad-Spectrum Antiviral Strategies and Nucleoside Analogues. Viruses. 2021 04 13; 13(4).
-
Different incidences of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without non-azithromycin antibiotics: A retrospective study. J Med Virol. 2021 Jul; 93(7):4411-4419.
-
Population Disequilibrium as Promoter of Adaptive Explorations in Hepatitis C Virus. Viruses. 2021 04 03; 13(4).
-
What if COVID-19 affects the child: which weapons and how to use them. Eur Rev Med Pharmacol Sci. 2021 Apr; 25(8):3325-3337.
-
In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase. Mol Divers. 2022 Feb; 26(1):279-292.
-
Successful treatment of positive-sense RNA virus coinfection with autoimmune hepatitis using double filtration plasmapheresis. BMJ Case Rep. 2021 Mar 25; 14(3).
-
[RNA polymerase: The Achilles heel of SARS-CoV-2]. Med Sci (Paris). 2021 03; 37(3):288-292.